Purpose: To evaluate the potential beneficial and synergistic effects of oral intake of a fixed combination of citicoline 500 mg plus homotaurine 50 mg (CIT/HOMO) on retinal ganglion cell (RGC) function in subjects with glaucoma using pattern electroretinogram (PERG) and to investigate the effects on visual field and quality of life.
Methods: Consecutive patients with primary open-angle glaucoma with controlled IOP (<18 mmHg) receiving beta-blockers and prostaglandin analogs alone or as combination therapy (fixed or un-fixed); with stable disease (progression no more than -1 dB/year at the visual field MD); and an early to moderate visual field defect (MD < -12 dB) were randomized to: arm A. topical therapy + CIT/HOMO for 4 months, 2 months of wash out, 4 months of topical therapy alone; arm B. topical therapy alone for 4 months, topical therapy + CIT/HOMO for 4 months, 2 months of wash out. All patients underwent 4 visits: complete ocular examination, visual field, PERG and quality of life assessment (NEI-VFQ25) were performed at each visit.
Results: Fifty-seven patients completed the study: 26 in group A and 31 in group B. At the end of the intake period, PERG's P50 and N95 waves recorded a greater amplitude. The increase was statistically significant in the inferior and superior P50 waves amplitude: 0.47 μV (95%CI, 0.02-0.93; = 0.04) and 0.65 μV (95% CI, 0.16-1.13; = 0.009), respectively, and in the inferior N95 wave amplitude 0.63 μV (95% CI, 0.22-1.04; = 0.002). A significantly shorter peak time of 3.3 μV (95% CI, -6.01- -0.54; = 0.01) was observed for the superior P50 wave only.
Conclusions: Daily oral intake of the fixed combination CIT/HOMO for 4 months improved the function of inner retinal cells recorded by PERG in the inferior and in the superior quadrants, independently from IOP reduction. This interesting association could represent a valid option for practicing neuromodulation in patients with glaucoma to prevent disease progression.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106378 | PMC |
http://dx.doi.org/10.3389/fmed.2022.882335 | DOI Listing |
Am J Cardiovasc Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Oral bempedoic acid (NEXLETOL in the USA; Nilemdo in the EU) and the fixed dose combination (FDC) of bempedoic acid/ezetimibe (NEXLIZET in the USA; Nustendi in the EU) are approved to reduce cardiovascular (CV) risk in statin-intolerant patients who are at high risk for, or have, CV disease. A first-in-class therapy, bempedoic acid inhibits the adenosine triphosphate-citrate lyase enzyme in the cholesterol biosynthesis pathway. In the multinational phase III CLEAR Outcomes trial in statin-intolerant patients, once-daily bempedoic acid 180 mg significantly reduced the risk of the primary endpoint (a four-component major adverse CV event composite of CV death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization) compared with placebo.
View Article and Find Full Text PDFClocks Sleep
January 2025
Circadian Physics Group, School of Physics, University of Sydney, Sydney, NSW 2006, Australia.
Fixed sleep schedules with an 8 h time in bed (TIB) are used to ensure participants are well-rested before laboratory studies. However, such schedules may lead to cumulative excess wakefulness in young individuals. Effects on older individuals are unknown.
View Article and Find Full Text PDFJAMIA Open
February 2025
Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, ON M5B 1T8, Canada.
Objectives: Deidentification of personally identifiable information in free-text clinical data is fundamental to making these data broadly available for research. However, there exist gaps in the deidentification landscape with regard to the functionality and flexibility of extant tools, as well as suboptimal tradeoffs between deidentification accuracy and speed. To address these gaps and tradeoffs, we develop a new Python-based deidentification software, pyDeid.
View Article and Find Full Text PDFJBI Evid Synth
January 2025
RISE-Health, Nursing School of Porto, Porto, Portugal.
Objective: The objective of this review is to evaluate the effectiveness of combined physical and psychological interventions on anxiety and depression symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Introduction: By 2030, COPD is expected to be the third-leading cause of death and the seventh in terms of overall health impact, measured in disability-adjusted life years. As with other comorbidities, anxiety and depression disorders influence the prognosis.
Cell Biosci
January 2025
Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, 26 Yuancun Erheng Road, Guangzhou, 510655, Guangdong, China.
Background: Intratumoral heterogeneity emerges from accumulating genetic and epigenetic changes during tumorigenesis, which may contribute to therapeutic failure and drug resistance. However, the lack of a quick and convenient approach to determine the intratumoral epigenetic heterogeneity (eITH) limit the application of eITH in clinical settings. Here, we aimed to develop a tool that can evaluate the eITH using the DNA methylation profiles from bulk tumors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!